|Speaker:||Dr. Julia Ljubimova|
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||A nanobiopolymer for drug delivery based on polymalic acid (PMLA) was invented by scientists from Arrogene Inc. and Cedars-Sinai Medical Center, Los Angeles. A significant feature of novel drug, based on this universal nanoplatform, is its ability to target multimeric tumor-associated proteins with one drug, a capability that other existing agents do not have. We have shown a significant anti-tumor and anti-angiogenic activity of this drug, Polycefin.
Two antisense oligonucleotide inhibitors of synthesis of chains of laminin-411 a tumor vascular wall protein, were delivered simultaneously to brain tumor cells using antibody attached to the PMLA-based drug delivery molecule, Polycefin. Evidence is presented that the delivery system passes through the blood-brain and blood-tumor barriers. The inhibitors targeted α4 and β1 chains of laminin-411 and inhibited their synthesis in vitro and in vivo. Treatment of glioma-bearing animals with Polycefin significantly diminished tumor vascularity and significantly increased animal survival (p<0.004). This nanoscale drug delivery system, Polycefin, proved a suitable device for the targeted in vivo delivery of antisense oligonucleotides/siRNA/chemotherapeutical drugs/monoclonal antibodies specifically to the tumor cells.
|Venture is:||Seed Level|